Q2 2026 revenue grew 22% year-over-year to $382.5 million, with strong gains in Oncology Diagnostics and Data Licensing. Net income reached $5.6 million, and guidance for 2026 revenue was raised to $1.595–$1.605 billion. Announced $1.5 billion Personalis acquisition.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.